JP2005524410A5

JP2005524410A5 -

Download PDF

Info

Publication number: JP2005524410A5
Authority: JP; Japan
Prior art keywords: apoptosis; cells; eif; phm6; rat
Prior art date: 2003-05-07
Legal status : Granted

Application number

JP2004503607A

Other languages

English (en)

Japanese (ja)

Other versions

JP4754819B2 (ja

JP2005524410A (ja

Filing date

2003-05-07

Publication date

2006-06-22

2002-05-07 Priority claimed from US10/141,647 external-priority patent/US7166467B2/en

2002-07-23 Priority claimed from US10/200,148 external-priority patent/US7968523B2/en

2003-05-07 Application filed filed Critical

2005-08-18 Publication of JP2005524410A publication Critical patent/JP2005524410A/ja

2006-06-22 Publication of JP2005524410A5 publication Critical patent/JP2005524410A5/ja

2011-08-24 Application granted granted Critical

2011-08-24 Publication of JP4754819B2 publication Critical patent/JP4754819B2/ja

2023-05-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

210000004027 cell Anatomy 0.000 description 333
108010085279 eukaryotic translation initiation factor 5A Proteins 0.000 description 241
102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 description 232
230000006907 apoptotic process Effects 0.000 description 177
102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 167
108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 167
241000700159 Rattus Species 0.000 description 136
108090000623 proteins and genes Proteins 0.000 description 94
102000048231 Deoxyhypusine synthases Human genes 0.000 description 90
108700023218 Deoxyhypusine synthases Proteins 0.000 description 90
108020004414 DNA Proteins 0.000 description 88
108090000765 processed proteins & peptides Proteins 0.000 description 66
102000004196 processed proteins & peptides Human genes 0.000 description 60
102000004169 proteins and genes Human genes 0.000 description 60
229920001184 polypeptide Polymers 0.000 description 59
235000018102 proteins Nutrition 0.000 description 59
238000000034 method Methods 0.000 description 53
150000007523 nucleic acids Chemical class 0.000 description 51
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 51
230000001640 apoptogenic effect Effects 0.000 description 49
102000039446 nucleic acids Human genes 0.000 description 48
108020004707 nucleic acids Proteins 0.000 description 48
239000012528 membrane Substances 0.000 description 44
239000002299 complementary DNA Substances 0.000 description 40
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 38
239000002773 nucleotide Substances 0.000 description 38
125000003729 nucleotide group Chemical group 0.000 description 38
238000011282 treatment Methods 0.000 description 37
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 36
206010028980 Neoplasm Diseases 0.000 description 36
230000014509 gene expression Effects 0.000 description 36
238000001890 transfection Methods 0.000 description 36
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 35
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 35
238000001262 western blot Methods 0.000 description 35
108091032973 (ribonucleotides)n+m Proteins 0.000 description 34
210000004246 corpus luteum Anatomy 0.000 description 33
239000000523 sample Substances 0.000 description 31
230000006870 function Effects 0.000 description 30
230000000875 corresponding effect Effects 0.000 description 29
239000000243 solution Substances 0.000 description 29
239000002609 medium Substances 0.000 description 27
241001465754 Metazoa Species 0.000 description 26
239000012634 fragment Substances 0.000 description 26
239000002953 phosphate buffered saline Substances 0.000 description 26
210000001519 tissue Anatomy 0.000 description 26
238000013467 fragmentation Methods 0.000 description 25
238000006062 fragmentation reaction Methods 0.000 description 25
229940063673 spermidine Drugs 0.000 description 25
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
201000011510 cancer Diseases 0.000 description 24
125000003275 alpha amino acid group Chemical group 0.000 description 23
238000010240 RT-PCR analysis Methods 0.000 description 22
239000000126 substance Substances 0.000 description 22
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
239000013604 expression vector Substances 0.000 description 21
239000007924 injection Substances 0.000 description 21
238000002347 injection Methods 0.000 description 21
239000000203 mixture Substances 0.000 description 21
108010092160 Dactinomycin Proteins 0.000 description 19
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 19
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 19
229960000640 dactinomycin Drugs 0.000 description 19
230000000694 effects Effects 0.000 description 19
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 18
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 18
238000001514 detection method Methods 0.000 description 18
210000002966 serum Anatomy 0.000 description 18
238000011534 incubation Methods 0.000 description 17
229920000768 polyamine Polymers 0.000 description 17
230000014616 translation Effects 0.000 description 17
239000013598 vector Substances 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 16
238000009396 hybridization Methods 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
238000002474 experimental method Methods 0.000 description 14
230000006882 induction of apoptosis Effects 0.000 description 14
230000000938 luteal effect Effects 0.000 description 14
239000013612 plasmid Substances 0.000 description 14
239000000047 product Substances 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 14
101710154606 Hemagglutinin Proteins 0.000 description 13
101710093908 Outer capsid protein VP4 Proteins 0.000 description 13
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 13
101710176177 Protein A56 Proteins 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 13
239000000185 hemagglutinin Substances 0.000 description 13
230000002062 proliferating effect Effects 0.000 description 13
108091034117 Oligonucleotide Proteins 0.000 description 12
101001002417 Rattus norvegicus Eukaryotic translation initiation factor 5A-1 Proteins 0.000 description 12
230000004913 activation Effects 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
239000003814 drug Substances 0.000 description 12
108020004999 messenger RNA Proteins 0.000 description 12
108091003079 Bovine Serum Albumin Proteins 0.000 description 11
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 11
239000012091 fetal bovine serum Substances 0.000 description 11
230000035772 mutation Effects 0.000 description 11
210000001672 ovary Anatomy 0.000 description 11
230000036961 partial effect Effects 0.000 description 11
241000894007 species Species 0.000 description 11
210000004881 tumor cell Anatomy 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
102000011727 Caspases Human genes 0.000 description 10
108010076667 Caspases Proteins 0.000 description 10
102000003992 Peroxidases Human genes 0.000 description 10
108010029485 Protein Isoforms Proteins 0.000 description 10
102000001708 Protein Isoforms Human genes 0.000 description 10
230000005775 apoptotic pathway Effects 0.000 description 10
239000000834 fixative Substances 0.000 description 10
239000000499 gel Substances 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
108040007629 peroxidase activity proteins Proteins 0.000 description 10
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 10
238000003146 transient transfection Methods 0.000 description 10
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 9
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
240000004808 Saccharomyces cerevisiae Species 0.000 description 9
239000000074 antisense oligonucleotide Substances 0.000 description 9
238000012230 antisense oligonucleotides Methods 0.000 description 9
238000010367 cloning Methods 0.000 description 9
238000010186 staining Methods 0.000 description 9
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
108020005345 3' Untranslated Regions Proteins 0.000 description 8
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
101001054354 Homo sapiens Eukaryotic translation initiation factor 5A-1 Proteins 0.000 description 8
102000040945 Transcription factor Human genes 0.000 description 8
108091023040 Transcription factor Proteins 0.000 description 8
239000011543 agarose gel Substances 0.000 description 8
230000000692 anti-sense effect Effects 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
201000010099 disease Diseases 0.000 description 8
229940079593 drug Drugs 0.000 description 8
230000002779 inactivation Effects 0.000 description 8
210000004940 nucleus Anatomy 0.000 description 8
229920002981 polyvinylidene fluoride Polymers 0.000 description 8
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
238000013519 translation Methods 0.000 description 8
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 7
102000029816 Collagenase Human genes 0.000 description 7
108060005980 Collagenase Proteins 0.000 description 7
101710135898 Myc proto-oncogene protein Proteins 0.000 description 7
102100038895 Myc proto-oncogene protein Human genes 0.000 description 7
101710150448 Transcriptional regulator Myc Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
229960002424 collagenase Drugs 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
239000012636 effector Substances 0.000 description 7
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
230000006698 induction Effects 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000001243 protein synthesis Methods 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
238000011144 upstream manufacturing Methods 0.000 description 7
102000002260 Alkaline Phosphatase Human genes 0.000 description 6
108020004774 Alkaline Phosphatase Proteins 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 6
241000196324 Embryophyta Species 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
238000000636 Northern blotting Methods 0.000 description 6
108700020796 Oncogene Proteins 0.000 description 6
238000002105 Southern blotting Methods 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000004663 cell proliferation Effects 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 6
239000000284 extract Substances 0.000 description 6
238000000684 flow cytometry Methods 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
239000003446 ligand Substances 0.000 description 6
235000013336 milk Nutrition 0.000 description 6
239000008267 milk Substances 0.000 description 6
210000004080 milk Anatomy 0.000 description 6
230000000877 morphologic effect Effects 0.000 description 6
230000037361 pathway Effects 0.000 description 6
230000025915 regulation of apoptotic process Effects 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
239000002033 PVDF binder Substances 0.000 description 5
241000282320 Panthera leo Species 0.000 description 5
239000005700 Putrescine Substances 0.000 description 5
239000004904 UV filter Substances 0.000 description 5
241000700605 Viruses Species 0.000 description 5
102000055102 bcl-2-Associated X Human genes 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
230000008859 change Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
PGPFBXMCOQNMJO-VIFPVBQESA-N deoxyhypusine Chemical group NCCCCNCCCC[C@H](N)C(O)=O PGPFBXMCOQNMJO-VIFPVBQESA-N 0.000 description 5
102000006735 deoxyhypusine hydroxylase Human genes 0.000 description 5
108010028753 deoxyhypusine hydroxylase Proteins 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
239000002502 liposome Substances 0.000 description 5
230000008569 process Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
239000012192 staining solution Substances 0.000 description 5
238000010254 subcutaneous injection Methods 0.000 description 5
239000007929 subcutaneous injection Substances 0.000 description 5
230000003827 upregulation Effects 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
102000000412 Annexin Human genes 0.000 description 4
108050008874 Annexin Proteins 0.000 description 4
241000283707 Capra Species 0.000 description 4
208000005623 Carcinogenesis Diseases 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
108091033380 Coding strand Proteins 0.000 description 4
238000007399 DNA isolation Methods 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
-1 Hoerscht 33258 Chemical class 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
206010027476 Metastases Diseases 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
108091036066 Three prime untranslated region Proteins 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
238000007792 addition Methods 0.000 description 4
230000004075 alteration Effects 0.000 description 4
230000027455 binding Effects 0.000 description 4
239000012148 binding buffer Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000036952 cancer formation Effects 0.000 description 4
231100000504 carcinogenesis Toxicity 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000010428 chromatin condensation Effects 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
239000008367 deionised water Substances 0.000 description 4
229910021641 deionized water Inorganic materials 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
229960005542 ethidium bromide Drugs 0.000 description 4
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
239000006260 foam Substances 0.000 description 4
BZUIJMCJNWUGKQ-BDAKNGLRSA-N hypusine Chemical compound NCC[C@@H](O)CNCCCC[C@H](N)C(O)=O BZUIJMCJNWUGKQ-BDAKNGLRSA-N 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000009401 metastasis Effects 0.000 description 4
229940049954 penicillin Drugs 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229960005322 streptomycin Drugs 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
230000005945 translocation Effects 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
108010077544 Chromatin Proteins 0.000 description 3
108010067770 Endopeptidase K Proteins 0.000 description 3
101710126270 Eukaryotic translation initiation factor 5A-1 Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
101000844963 Homo sapiens Deoxyhypusine synthase Proteins 0.000 description 3
KDYRQBCJBKCHIQ-UHFFFAOYSA-N Hypusin Natural products NCC(O)CNCCCCC(N)C(=O)O KDYRQBCJBKCHIQ-UHFFFAOYSA-N 0.000 description 3
239000004677 Nylon Substances 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
238000002123 RNA extraction Methods 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010042573 Superovulation Diseases 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
230000030833 cell death Effects 0.000 description 3
210000003483 chromatin Anatomy 0.000 description 3
238000004737 colorimetric analysis Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
230000007423 decrease Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000005865 ionizing radiation Effects 0.000 description 3
238000002372 labelling Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000006654 negative regulation of apoptotic process Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
239000008188 pellet Substances 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
230000001124 posttranscriptional effect Effects 0.000 description 3
238000000751 protein extraction Methods 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000009758 senescence Effects 0.000 description 3
229940063675 spermine Drugs 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
101150013449 DHS gene Proteins 0.000 description 2
240000006497 Dianthus caryophyllus Species 0.000 description 2
235000009355 Dianthus caryophyllus Nutrition 0.000 description 2
206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
206010064571 Gene mutation Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
240000004658 Medicago sativa Species 0.000 description 2
235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 2
101001002432 Mus musculus Eukaryotic translation initiation factor 5A-1 Proteins 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
244000088415 Raphanus sativus Species 0.000 description 2
235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
101100232702 Rattus norvegicus Eif5a gene Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
240000003768 Solanum lycopersicum Species 0.000 description 2
108700012411 TNFSF10 Proteins 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
238000012867 alanine scanning Methods 0.000 description 2
230000002424 anti-apoptotic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000033077 cellular process Effects 0.000 description 2
238000002038 chemiluminescence detection Methods 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000007865 diluting Methods 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
101150074736 eif5a gene Proteins 0.000 description 2
230000009462 endogenous apoptosis Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000033444 hydroxylation Effects 0.000 description 2
238000005805 hydroxylation reaction Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
238000002955 isolation Methods 0.000 description 2
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000011068 loading method Methods 0.000 description 2
210000002596 lutein cell Anatomy 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000000861 pro-apoptotic effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
238000002864 sequence alignment Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
235000020183 skimmed milk Nutrition 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000012096 transfection reagent Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000005751 tumor progression Effects 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
238000012800 visualization Methods 0.000 description 2
238000010792 warming Methods 0.000 description 2
PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical group NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 description 1
ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
108090000672 Annexin A5 Proteins 0.000 description 1
102000004121 Annexin A5 Human genes 0.000 description 1
241000203069 Archaea Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
108091008875 B cell receptors Proteins 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
101000692466 Bos taurus Prostaglandin F synthase 2 Proteins 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
102100032231 Caveolae-associated protein 2 Human genes 0.000 description 1
108050005259 Caveolae-associated protein 2 Proteins 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
102000005927 Cysteine Proteases Human genes 0.000 description 1
108010005843 Cysteine Proteases Proteins 0.000 description 1
102100030497 Cytochrome c Human genes 0.000 description 1
108010075031 Cytochromes c Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102100021002 Eukaryotic translation initiation factor 5A-2 Human genes 0.000 description 1
101710145505 Fiber protein Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000287826 Gallus Species 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101900102211 Human T-cell leukemia virus 1 Protein Rex Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
241000764238 Isis Species 0.000 description 1
101710128836 Large T antigen Proteins 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
108091005461 Nucleic proteins Chemical group 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000015537 Protein Kinase C-alpha Human genes 0.000 description 1
108010050276 Protein Kinase C-alpha Proteins 0.000 description 1
101710150344 Protein Rev Proteins 0.000 description 1
102000044126 RNA-Binding Proteins Human genes 0.000 description 1
108700020471 RNA-Binding Proteins Proteins 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
101000928655 Rattus norvegicus Deoxyhypusine synthase Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
208000007014 Retinitis pigmentosa Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
244000019194 Sorbus aucuparia Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
108010084938 adenovirus receptor Proteins 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
229940076005 apoptosis modulator Drugs 0.000 description 1
208000034615 apoptosis-related disease Diseases 0.000 description 1
230000009925 apoptotic mechanism Effects 0.000 description 1
NMYKBZSMOUFOJV-FJSWQEPZSA-N aprinocarsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 NMYKBZSMOUFOJV-FJSWQEPZSA-N 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
229940065181 bacillus anthracis Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
101150024147 bax gene Proteins 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000002775 capsule Substances 0.000 description 1
201000011529 cardiovascular cancer Diseases 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
239000012707 chemical precursor Substances 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
108010045839 eIF-5A2 Proteins 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000010502 episomal replication Effects 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000004345 fruit ripening Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000003128 head Anatomy 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
PWSKHLMYTZNYKO-UHFFFAOYSA-N heptane-1,7-diamine Chemical compound NCCCCCCCN PWSKHLMYTZNYKO-UHFFFAOYSA-N 0.000 description 1
229940084986 human chorionic gonadotropin Drugs 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000640 hydroxylating effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000006164 hypusine formation Effects 0.000 description 1
238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000012739 integrated shape imaging system Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000014634 leaf senescence Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
230000003990 molecular pathway Effects 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000021616 negative regulation of cell division Effects 0.000 description 1
208000025189 neoplasm of testis Diseases 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000004987 nonapoptotic effect Effects 0.000 description 1
210000004492 nuclear pore Anatomy 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
230000025308 nuclear transport Effects 0.000 description 1
229960000435 oblimersen Drugs 0.000 description 1
MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
238000005222 photoaffinity labeling Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
210000002729 polyribosome Anatomy 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000018883 protein targeting Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000028617 response to DNA damage stimulus Effects 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
235000006414 serbal de cazadores Nutrition 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
208000002320 spinal muscular atrophy Diseases 0.000 description 1
238000009987 spinning Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000037351 starvation Effects 0.000 description 1
239000012058 sterile packaged powder Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000026727 thymocyte apoptotic process Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000025366 tissue development Effects 0.000 description 1
230000030968 tissue homeostasis Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
208000025421 tumor of uterus Diseases 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000024719 uterine cervix neoplasm Diseases 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000004170 yolk cell Anatomy 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Images

JP2004503607A 2002-05-07 2003-05-07 アポトーシス調節に関する核酸、ポリペプチド及び方法 Expired - Fee Related JP4754819B2 (ja)